Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-09-30
Target enrollment:
Participant gender:
Summary
This study consists of Part A for monotherapy and Part B for combination therapy to evaluate
safety, tolerability, pharmacokinetics, and preliminary efficacy of TU2218 in patients with
advanced solid tumors. The main purpose of Phase 1 is to determined the recommended Phase 2
dose (RP2D) of TU2218 and the main purpose of Phase 2 is to evaluate the antitumor activity
of TU2218 at RP2D.